111 related articles for article (PubMed ID: 7623998)
1. Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients.
Llopart R; Doñate T; Oliva JA; Rodá M; Rousaud F; Gonzalez-Sastre F; Pedreño J; Ordoñez-Llanos J
Nephrol Dial Transplant; 1995; 10(4):537-40. PubMed ID: 7623998
[TBL] [Abstract][Full Text] [Related]
2. Effects of three treatment modes on plasma lipids and lipoproteins in uraemic patients.
Hörkkö S; Huttunen K; Läärä E; Kervinen K; Kesäniemi YA
Ann Med; 1994 Aug; 26(4):271-82. PubMed ID: 7946245
[TBL] [Abstract][Full Text] [Related]
3. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.
Nishizawa Y; Shoji T; Emoto M; Kawasaki K; Konishi T; Tabata T; Inoue T; Morii H
Clin Nephrol; 1995 Apr; 43(4):268-77. PubMed ID: 7606882
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P
Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
[TBL] [Abstract][Full Text] [Related]
5. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients.
Nishizawa Y; Shoji T; Tabata T; Inoue T; Morii H
Kidney Int Suppl; 1999 Jul; 71():S134-6. PubMed ID: 10412757
[TBL] [Abstract][Full Text] [Related]
6. Lipid transfer inhibitor protein activity deficiency in normolipidemic uremic patients on continuous ambulatory peritoneal dialysis.
Serdyuk AP; Morton RE
Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1716-24. PubMed ID: 9327768
[TBL] [Abstract][Full Text] [Related]
7. Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose.
Heimbürger O; Stenvinkel P; Berglund L; Tranoeus A; Lindholm B
Nephron; 1996; 72(2):135-44. PubMed ID: 8684516
[TBL] [Abstract][Full Text] [Related]
8. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis.
Lindholm B; Norbeck HE
Acta Med Scand; 1986; 220(2):143-51. PubMed ID: 3776689
[TBL] [Abstract][Full Text] [Related]
9. The determination of insulin sensitivity in hemodialysis and continuous ambulatory peritoneal dialysis in nondiabetic patients with end-stage renal disease.
Tuzcu A; Bahceci M; Yilmaz ME; Turgut C; Kara IH
Saudi Med J; 2005 May; 26(5):786-91. PubMed ID: 15951871
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency.
Lee DM; Knight-Gibson C; Samuelsson O; Attman PO; Wang CS; Alaupovic P
Kidney Int; 2002 Jan; 61(1):209-18. PubMed ID: 11786103
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels.
Kagan A; Bar-Khayim Y; Schafer Z; Fainaru M
Kidney Int; 1990 Mar; 37(3):980-90. PubMed ID: 2313985
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
González AI; Schreier L; Elbert A; Berg G; Beresan H; López G; Wikinski R
Metabolism; 2003 Jan; 52(1):116-21. PubMed ID: 12524671
[TBL] [Abstract][Full Text] [Related]
13. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
Milionis HJ; Elisaf MS; Karabina SA; Bairaktari E; Tselepis AD; Siamopoulos KC
Kidney Int; 1999 Dec; 56(6):2276-85. PubMed ID: 10594806
[TBL] [Abstract][Full Text] [Related]
14. Lipids, lipoproteins and apolipoproteins abnormalities in patients undergoing dialysis.
Yang X; Wang H; Zhu Z; Deng A
J Tongji Med Univ; 1997; 17(2):126-8. PubMed ID: 9639806
[TBL] [Abstract][Full Text] [Related]
15. Lipids, lipoproteins and apolipoproteins A-I and B and apolipoprotein losses in continuous ambulatory peritoneal dialysis.
Steele J; Billington T; Janus E; Moran J
Atherosclerosis; 1989 Sep; 79(1):47-50. PubMed ID: 2803346
[TBL] [Abstract][Full Text] [Related]
16. Twenty-four hour hormonal and metabolic profiles in uraemic patients before and during treatment with continuous ambulatory peritoneal dialysis.
Heaton A; Johnston DG; Haigh JW; Ward MK; Alberti KG; Kerr DN
Clin Sci (Lond); 1985 Oct; 69(4):449-57. PubMed ID: 4042546
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the humoral markers of bone turnover and bone mineral density in patients on haemodialysis and continuous ambulatory peritoneal dialysis.
Hampson G; Vaja S; Evans C; Chesters CA; Pettit R; Evans W; Thomas D; Seed PT; Fraser WD
Nephron; 2002 May; 91(1):94-102. PubMed ID: 12021525
[TBL] [Abstract][Full Text] [Related]
18. The effect of change of renal replacement therapy on serum lipoprotein (a) concentration.
Misra M; Webb AT; Reaveley DA; Doherty E; O'Donnell M; Seed M; Brown EA
Adv Perit Dial; 1997; 13():168-73. PubMed ID: 9360675
[TBL] [Abstract][Full Text] [Related]
19. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
[TBL] [Abstract][Full Text] [Related]
20. Effect of beta-blocker therapy on serum lipoprotein profiles in patients on renal dialysis and in diabetic nephropathy.
Kontessis PS; Jayathissa SA; Walker JD; Mattock MB; Williams DG; Viberti GC
Diabetes Res; 1993; 23(3):93-104. PubMed ID: 7712687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
